MarketReality
-
Stop Treating Cramer Calls Like Gospel — Marvell’s Crowded, Bausch Is a Gamble
Fade or Follow? Cramer’s Bullish Take on Marvell — and the Murky Bausch Call When Jim Cramer shouts “buy,” you’ve got two choices: grab a seat on the rocket or start looking for the exit. With Marvell riding the AI wave and Bausch Health limping through its turnaround, blindly following either call isn’t a strategy.…
-
Cramer Doesn’t Make You Money — Fundamentals Do
Can you actually make money off a Cramer call — or are you just buying TV noise? Let’s test it with two names that couldn’t be more different: Marvell Technology (MRVL), riding the AI infrastructure wave, and Bausch Health (BHC), the poster child for debt-fueled excess trying to claw its way back. One is momentum…
-
Buying the Bounce Is Not a Strategy — And Cramer’s Picks Prove It
Jim Cramer says buy Marvell and Bausch Health. Fine. But are these actually smart entries right now — or just classic “it’s been crushed, so it must bounce” trades? Let’s separate signal from noise. Marvell (MRVL): Riding the AI Wave — But Timing Matters Marvell isn’t some speculative chip name. It’s a serious data infrastructure…
-
AI Stocks Aren’t Overpriced — Expectations Are
AI stocks aren’t expensive because the future is bright. They’re expensive because investors are confusing inevitability with inevitability of profits. And that mistake is quietly warping how the market prices the real infrastructure winners: NVIDIA, hyperscale cloud providers, and the data platforms everyone claims to need. Here’s the uncomfortable truth. AI is real. The spending…
You must be logged in to post a comment.